

# JCRPE

*Journal of Clinical Research in Pediatric Endocrinology*

March 2018

volume 10

issue 1

[www.jcrpe.org](http://www.jcrpe.org)

ISSN: 1308-5727

E-ISSN: 1308-5735



Official Journal of  
Turkish Pediatric Endocrinology  
and Diabetes Society

## Editor in Chief

### Feyza Darendeliler

Istanbul University Istanbul Faculty of Medicine, Department of Pediatric Endocrinology, Istanbul, Turkey  
feyzad@istanbul.edu.tr ORCID-ID: orcid.org/0000-0003-4786-0780

## Associate Editors

### Abdullah Bereket

Marmara University Faculty of Medicine, Department of Pediatric Endocrinology, Istanbul, Turkey  
abdullahbereket@gmail.com ORCID-ID: orcid.org/0000-0002-6584-9043

### Damla Gökşen

Ege University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey  
damla.goksen@ege.edu.tr ORCID-ID: orcid.org/0000-0001-6108-0591

### Korcan Demir

Dokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey  
korcandemir@gmail.com ORCID-ID: orcid.org/0000-0002-8334-2422

### Samim Özen

Ege University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey  
samim.ozen@ege.edu.tr  
ORCID-ID: orcid.org/0000-0001-7037-2713

### Serap Turan

Marmara University Faculty of Medicine, Department of Pediatric Endocrinology, Istanbul, Turkey  
serap.turan@marmara.edu.tr ORCID-ID: orcid.org/0000-0002-5172-5402

## Editorial Advisor

### Olcay Neyzi

Emeritus Professor, Istanbul, Turkey  
oneyzi@superonline.com

## English Language Editor

Jeremy Jones, Kocaeli, Turkey

© The paper used to print this journal conforms to ISO 9706: 1994 standard (Requirements for Permanence).

The National Library of Medicine suggests that biomedical publications be printed on acid-free paper (alkaline paper).

Reviewing the articles' conformity to the publishing standards of the Journal, typesetting, reviewing and editing the manuscripts and abstracts in English, creating links to source data, and publishing process are realized by Galenos.

## Editorial Board

### Ali Kemal Topaloğlu

Cukurova University Faculty of Medicine, Department of Pediatric Endocrinology, Adana, Turkey

### Angel Ferrandez Longas

Children's Hospital Miguel Servet, Department of Pediatric Endocrinology, Zaragoza, Spain

### Aysun Bideci

Gazi University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey

### Fima Lifshitz

Pediatric Sunshine Academics, Inc., Santa Barbara, USA

### Hüseyin Onay

Ege University Faculty of Medicine, Department of Medical Genetics, İzmir, Turkey

### İlknur Arslanoğlu

Düzce University Faculty of Medicine, Department of Pediatric Endocrinology, Düzce, Turkey

### Khalid Hussain

Great Ormond Street Hospital for Children, Department of Pediatric Endocrinology, London, United Kingdom

### Merih Berberoğlu

Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey

### Mitchell Geffner

Children's Hospital Los Angeles, Center for Endocrinology, Diabetes and Metabolism, Los Angeles, USA

### Neslihan Güngör

Louisiana State University Health Sciences Center-Shreveport, Department of Pediatric Endocrinology, Louisiana, USA

### Nurgün Kandemir

Hacettepe University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey

### Oktay Özdemir (Statistical Consultant)

Yorum Consultancy Limited Company, Istanbul, Turkey

### Ömer Tarım

Uludağ University Faculty of Medicine, Department of Pediatric Endocrinology, Bursa, Turkey

### Pietro Galassetti

University of California, Pediatric Exercise and Genomics Research Center, Department of Pediatrics, California, USA

### Robert Rapaport

Icahn School of Medicine at Mount Sinai, Kravis Children's Hospital at Mount Sinai, Department of Pediatric Endocrinology and Diabetes, New York, USA

### Sandra L. Blethen

Emeritus Professor, Belmont, CA, USA

### Thomas Allen Wilson

Stony Brook Children's Hospital, Department of Pediatric Endocrinology, New York, USA

### Wayne Cutfield

University of Auckland, Liggins Institute, Department of Pediatric Endocrinology, Auckland, New Zealand

## Publisher

Erkan Mor

## Publication Director

Nesrin Çolak

## Web Coordinators

Soner Yıldırım

Turgay Akpınar

## Web Assistants

Başak Yıldırım

## Graphics Department

Ayda Alaca

Çiğdem Birinci

## Project Coordinators

Eda Kolumsisa

Hatice Balta

Lütfiye Ayhan İrtem

Zeynep Altındağ

## Project Assistants

Esra Semerci

Günay Selimoğlu

Sedanur Sert

## Research&Development

Deniz Sleptsov

## Finance Coordinator

Sevinç Çakmak



## Contact

Address: Molla Gürani Mahallesi

Kaçamak Sokak

No: 21 34093

İstanbul-Turkey

Phone: +90 (212) 621 99 25

Fax: +90 (212) 621 99 27

E-mail: info@galenos.com.tr

Web Site: www.galenos.com.tr

## Printing at:

Creative Basım Ltd. Şti.

Litros Yolu 2. Matbaacılar Sit. ZD1

Topkapı, İstanbul-Turkey

Phone: +90 212 709 75 25

www.creativebasim.com

Date of printing: March 2018

ISSN: 1308-5727

E-ISSN: 1308-5735

## AIMS AND SCOPE

The Journal of Clinical Research in Pediatric Endocrinology (JCRPE) publishes original research articles, reviews, short communications, letters, case reports and other special features related to the field of pediatric endocrinology. JCRPE is published in English by the Turkish Pediatric Endocrinology and Diabetes Society quarterly (March, June, September, December). The target audience is physicians, researchers and other healthcare professionals in all areas of pediatric endocrinology.

JCRPE is indexed in EBSCO, SCOPUS, EMBASE, Engineering Village, Reaxys, Index Copernicus, CINAHL, GALE, Turk Medline, Tübitak Ulakbim TR Index, Index Medicus/PubMed, Türkiye Citation Index, PubMed Central (PMC), Science Citation Index-SCI-E and PubMed/MEDLINE.

JCRPE has an impact factor 1.118 in 2016.

The journal is printed on an acid-free paper.

## Permissions

Requests for permission to reproduce published material should be sent to the publisher.

Publisher: Erkan Mor

Address: Molla Gürani mah. Kaçamak Sok. 21/1 Fatih, Istanbul, Turkey

Telephone: +90 212 621 99 25

Fax: +90 212 621 99 27

Web page: <http://www.galenos.com.tr/en>

E-mail: [info@galenos.com.tr](mailto:info@galenos.com.tr)

## Copyright Notice

The author(s) hereby affirms that the manuscript submitted is original, that all statement asserted as facts are based on author(s) careful investigation and research for accuracy, that the manuscript does not, in whole or part, infringe any copyright, that it has not been published in total or in part and is not being submitted or considered for publication in total or in part elsewhere.

Completed Copyright Assignment&Affirmation of Originality Form will be faxed to the JCRPE Editorial Office (Fax: +90 212 621 99 27).

By signing this form,

1. Each author acknowledge that he/she participated in the work in a substantive way and is prepared to take public responsibility for the work.
2. Each author further affirms that he or she has read and understands the "Ethical Guidelines for Publication of Research".
3. The author(s), in consideration of the acceptance of the manuscript for publication, does hereby assign and transfer to the Journal of Clinical Research in Pediatric Endocrinology all of the rights and interest in and the copyright of the work in its current form and in any form subsequently revised for publication and/or electronic dissemination.

## Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

## GENERAL INFORMATION

Manuscripts must be written in English and must meet the requirements of the journal. Papers that do not meet these requirements will be returned to the author for necessary revision before the review. Manuscripts submitted to JCRPE are evaluated by peer reviewers. Authors of manuscripts requiring modifications have two months to resubmit a revised paper. Manuscripts returned after this deadline will be treated as new submissions. The journal is in compliance with the uniform requirements for manuscripts submitted to biomedical journals published by the International Committee of Medical Journal Editors (NEJM 1997; 336:309-315, updated 2001). Upon submission of the manuscript, authors are to indicate the type of trial/research and provide the checklist of the following guidelines when appropriate: Consort statement for randomized controlled trials (Moher D, Schultz KF, Altman D,

for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001 ; 285 : 1987 - 91), the QUOROM statement for meta-analysis and systemic reviews of randomized controlled trials (Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-Analyses. Lancet 1999; 354 : 1896 - 900) and the MOOSE guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008 - 12). Keywords are included according to MeSH (Medical Subject Headings) National Library of Medicine.

The Journal of Clinical Research in Pediatric Endocrinology publishes abstracts of accepted manuscripts online in advance of their publication in print. Another initiative is that the journal provides uncorrected full text PDF files via [www.jcrpe.org](http://www.jcrpe.org).

Once the manuscript is accepted, it receives a Digital Object Identifier (DOI) number.

## MANUSCRIPT CATEGORIES

All manuscripts must adhere to the limitations, as described below, for text only; the word count does not include the abstract, references, or figure/table legends. The word count must be noted on the title page, along with the number of figures and tables. Original Articles should be no longer than 5000 words and include no more than six figures and tables and 50 references.

Short Communications are short descriptions of focused studies with important, but very straightforward results. These manuscripts should be no longer than 2000 words, and include no more than two figures and tables and 20 references.

Brief Reports are discrete, highly significant findings reported in a shorter format. The abstract of the article should not exceed 150 words and the text/article length should not exceed 1200 words. References should be limited to 12, a maximum of 2 figures or tables.

Clinical Reviews address important topics in the field of pediatric endocrinology. Authors considering the submission of uninvited reviews should contact the editors in advance to determine if the topic that they propose is of current potential interest to the Journal. Reviews will be considered for publication only if they are written by authors who have at least three published manuscripts in the international peer reviewed journals and these studies should be cited in the review. Otherwise only invited reviews will be considered for peer review from qualified experts in the area. These manuscripts should be no longer than 6000 words and include no more than four figures and tables and 120 references.

Case Reports are descriptions of a case or small number of cases revealing novel and important insights into a condition's pathogenesis, presentation, and/or management. These manuscripts should be 2500 words or less, with four or fewer figures and tables and 30 or fewer references.

Consensus Statements may be submitted by professional societies. All such submission will be subjected to peer review, must be modifiable in response to criticisms, and will be published only if they meet the Journal's usual editorial standards. These manuscripts should typically be no longer than 4000 words and include no more than six figures and tables and 120 references.

Letters to the Editor may be submitted in response to work that has been published in the Journal. Letters should be short commentaries related to specific points of agreement or disagreement with the published work. Letters should be no longer than 500 words with no more than five complete references, and may not include any figures or tables.

## Note on Prior Publication

The journal publishes original research and review material. Material previously published in whole or in part shall not be considered for publication. At the time of submission, authors must report that the manuscript has not been published elsewhere. Abstracts or posters displayed at scientific meetings need not be reported.

## MANUSCRIPT SUBMISSION PROCEDURES

JCRPE only accepts electronic manuscript submission at the web site [www.jcrpe.org](http://www.jcrpe.org)

After logging on to the website [www.jcrpe.org](http://www.jcrpe.org) click 'online manuscript submission' icon. All corresponding authors should be provided a password and a username after providing the information needed. If you already have an account from a previous submission, enter your username and password to submit a new or revised manuscript. If you have forgotten your username and/or password, e-mail the editorial office for assistance. After logging on the article submission system with your own password and username please read carefully the directions of the system to provide all needed information. Attach the manuscript, tables and figures and additional documents.

### All Submissions Must Include:

1. A cover letter requesting that the manuscript be evaluated for publication in JCRPE and any information relevant to your manuscript. Cover letter should contain address, telephone, fax and e-mail address of the corresponding author.
2. Completed Copyright Assignment & Affirmation of Originality form. This form should be filled in thoroughly and faxed to the JCRPE Editorial Office at +90 212 621 99 27.
3. Completed Disclosure of Potential Conflict of Interest Form. The corresponding author must acquire all of the authors' completed disclosure forms and fax them to the editorial office at +90 212 621 99 27.

Authors must complete the online submission forms. If unable to successfully upload the files please contact the editorial office by e-mail.

JCRPE does not charge any fee for article submission or processing.

## MANUSCRIPT PREPARATION

### General Format

The Journal requires that all submissions be submitted according to these guidelines:

- Text should be double spaced with 2.5 cm margins on both sides using 12-point type in Times Roman font.
- All tables and figures must be placed after the text and must be labeled.
- Each section (abstract, text, references, tables, figures) should start on a separate page.
- Manuscripts should be prepared as word document (\*.doc) or rich text format (\*.rtf).

### Title Page

The title page should include the following:

- Full title
- Authors' names and institutions.
- Short title of not more than 40 characters for page headings
- At least three and maximum eight key words. Do not use abbreviations in the key words
- Word count (excluding abstract, figure legends and references)
- Corresponding author's e-mail and post address, telephone and fax numbers
- Name and address of person to whom reprint requests should be addressed
- Any grants or fellowships supporting the writing of the paper
- The ORCID (Open Researcher and Contributor ID) number of the all authors should be provided while sending the manuscript. A free registration can be done at <http://orcid.org>.

Structured Abstracts (According to the The Journal of the American Medical Association)

Original Articles should be submitted with structured abstracts of no more than 250 words. All information reported in the abstract must appear in the manuscript. The abstract should not include references. Please use complete sentences for all sections of the abstract. Structured abstract should include background, objective, methods, results and conclusion.

### What is already known on this topic?

### What this study adds?

These two items must be completed before submission. Each item should include at most 2-3 sentences and at most 50 words focusing on what is known and what this study adds.

Review papers do not need to include these boxes.

### Introduction

The article should begin with a brief introduction stating why the study was undertaken within the context of previous reports.

### Experimental Subjects

All clinical investigations described in submitted manuscripts must have been conducted in accordance with the guidelines in the Declaration of Helsinki and has been formally approved by the appropriate institutional review committees. All manuscripts must indicate that such approval was obtained and that informed consent was obtained from subjects in all experiments involving humans. The study populations should be described in detail. Subjects must be identified only by number or letter, not by initials or names. Photographs of patients' faces should be included only if scientifically relevant. Authors must obtain written consent from the patient for use of such photographs.

### Clinical Trials Registration

For clinical trial reports to be considered for publication in the Journal, prospective registration, as endorsed by the International Conference of Medical Journal Editors, is required. We recommend use of <http://www.clinicaltrials.gov>.

### Experimental Animals

A statement confirming that all animal experimentation described in the submitted manuscript was conducted in accord with accepted standards of humane animal care, according to the Declaration of Helsinki and Genova Convention, should be included in the manuscript.

### Materials and Methods

These should be described and referenced in sufficient detail for other investigators to repeat the work. Ethical consent should be included as stated above.

The name of the ethical committee, approval number should be stated.

### Results

The Results section should briefly present the experimental data in text, tables, and/or figures. Do not compare your observations with that of others in the results section.

### Discussion

The Discussion should focus on the interpretation and significance of the findings with concise objective comments that describe their relation to other work in that area and contain study limitations.

### Study Limitations

Limitations of the study should be detailed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.

### Conclusion

The conclusion of the study should be highlighted.

## Acknowledgments (Not Required for Submission)

An acknowledgment is given for contributors who may not be listed as authors, or for grant support of the research.

## Authorship Contribution

The kind of contribution of each author should be stated.

## References

References to the literature should be cited in numerical order (in parentheses) in the text and listed in the same numerical order at the end of the manuscript on a separate page or pages. The author is responsible for the accuracy of references.

Number of References: Case Report max 30 / Original Articles max 50

Examples of the reference style are given below. Further examples will be found in the articles describing the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (Ann Intern Med. 1988; 208:258-265, Br Med J. 1988; 296:401-405). The titles of journals should be abbreviated according to the style used in the Index Medicus.

Journal Articles and Abstracts: List all authors. The citation of unpublished observations, of personal communications is not permitted in the bibliography. The citation of manuscripts in press (i.e., accepted for publication) is permitted in the bibliography; the name of the journal in which they appear must be supplied. Citing an abstract is not recommended.

*Books:* List all authors or editors.

## Sample References

*Papers Published in Periodical Journals:* Gungor N, Saad R, Janosky J, Arslanian S. Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. *J Pediatr* 2004;144:47-55.

*Papers Only Published with DOI Numbers:* Knops NB, Sneeuw KC, Brand R, Hile ET, de Ouden AL, Wit JM, Verloove-Vanhorick SP. Catch-up growth up to ten years of age in children born very preterm or with very low birth weight. *BMC Pediatrics* 2005 doi: 10.1186/1471-2431-5-26.

*Book Chapters:* Darendeliler F. Growth Hormone Treatment in Rare Disorders: The KIGS Experience. In: Ranke MB, Price DA, Reiter EO (eds). *Growth Hormone Therapy in Pediatrics: 20 Years of KIGS*. Basel, Karger, 2007;213-239.

*Books:* Practical Endocrinology and Diabetes in Children. Raine JE, Donaldson MDC, Gregory JW, Savage MO. London, Blackwell Science, 2001;37-60.

## Tables

Tables must be constructed as simply as possible. Each table must have a concise heading and should be submitted on a separate page. Tables must not simply duplicate the text or figures. Number all tables in the order of their citation in the text. Include a title for each table (a brief phrase, preferably no longer than 10 to 15 words). Include all tables in a single file following the manuscript.

## Figures Legends

Figure legends and titles should be submitted on a separate page. Figure legends and titles should be clear and informative. Tables and figures should work under "windows". Number all figures (graphs, charts, photographs, and illustrations) in the order of their citation in the text. Include a title for each figure (a brief phrase, preferably no longer than 10 to 15 words).

## Figures & Images

At submission, the following file formats are acceptable: AI, EMF, EPS, JPG, PDF, PPT, PSD, TIF. Figures may be embedded at the end of the manuscript text file or loaded as separate files for submission purposes.

All images MUST be at or above intended display size, with the following image resolutions: Line Art 800 dpi, Combination (Line Art + Halftone) 600 dpi, Halftone 300 dpi. See the Image quality specifications chart for details. Image files also must be cropped as close to the actual image as possible.

## Units of Measure

Results should be expressed in metric units.

## Validation of Data and Statistical Analysis

Assay validation: Bioassay and radioimmunoassay potency estimates should be accompanied by an appropriate measure of the precision of these estimates. For bioassays, these usually will be the standard deviation, standard error of the mean, confidence limits. For both bioassays and radioimmunoassays, it is necessary to include data relating to within-assay and between-assay variability. If all relevant comparisons are made within the same assay, the latter may be omitted. Statistical analysis should be done accurately and with precision. Please consult a statistician if necessary.

## Proofs and Reprints

Proofs and a reprint order are sent to the corresponding author. The author should designate by footnote on the title page of the manuscript the name and address of the person to whom reprint requests should be directed. The manuscript when published will become the property of the journal.

## Page and Other Charges

### Archiving

The editorial office will retain all manuscripts and related documentation (correspondence, reviews, etc.) for 12 months following the date of publication or rejection.

### Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in Microsoft Word, RTF, or WordPerfect document file format. The text is double-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end. Please do not send the manuscript in docx.
3. Where available, URLs for the references have been provided.
4. Upon acceptance of your manuscript for publication, a completed Copyright Assignment & Affirmation of Originality Form will be faxed to the JCRPE Editorial Office (Fax: +90 212 621 99 27)
5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
6. Completed Disclosure of Potential Conflict of Interest Form. The corresponding author must acquire all of the authors' completed disclosure forms and fax them, together, to the editorial office along with the Author Disclosure Summary.

### Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

### Peer Review Process

1. The manuscript is assigned to an editor, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities.
2. For those manuscripts sent for external peer review, the editor assigns reviewers to the manuscript.
3. The reviewers review the manuscript.
4. The editor makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations.
5. The decision letter is sent to the author.

### The Reviewer is Asked to Focus on the Following Issues:

1. **General recommendation about the manuscript**  
How original is the manuscript?

Is it well presented?  
How is the length of the manuscript?

**2. Publication timing, quality, and priority**

How important is the manuscript in this field?  
Does it present original data?  
Does it carry priority in publishing?

**3. Specific questions regarding the quality of the manuscript**

Does the title describe the study accurately?  
Is the abstract informative and clear?  
Do the authors state the study question in the introduction?  
Are the methods clear?  
Are ethical guidelines met?  
Are statistical analyses appropriate?  
Are the results presented clearly?

Does the discussion cover all of the findings?  
Are the references appropriate for the manuscript?

**4. Remarks to the editor**

Accepted in its present form  
Accepted after modest revisions  
Reconsidered for acceptance after major changes  
Rejected

**5. Remarks to the author**

What would be your recommendations to the author?  
Conflict of interest statement for the reviewer (Please state if a conflict of interest is present)  
For further instructions about how to review, see Reviewing Manuscripts for Archives of Pediatrics & Adolescent Medicine by Peter Cummings, MD, MPH; Frederick P. Rivara, MD, MPH in Arch Pediatr Adolesc Med. 2002;156:11-13.



## Original Articles

- 1** Acute Effects of Blood Transfusion on Insulin Sensitivity and Pancreatic  $\beta$ -Cell Function in Children with  $\beta$ -Thalassemia/Hemoglobin E Disease  
*Somboon Wankanit, Ampaiwan Chuansumrit, Preamrudee Poomthavorn, Patcharin Khlairit, Saruny Pongratanakul, Pat Mahachoklertwattana, (Bangkok, Thailand)*
- 8** Serum Nesfatin-1 Levels in Girls with Idiopathic Central Precocious Puberty  
*Ayça Altıncık, Oya Sayın, (Denizli, İzmir, Turkey)*
- 13** An Assessment of Retinal Nerve Fiber Layer Thickness in Non-Diabetic Obese Children and Adolescents  
*Bediz Özen, Hakan Öztürk, Gönül Çatlı, Bumin Dünder, (İzmir, Turkey)*
- 19** Could Alerting Physicians for Low Alkaline Phosphatase Levels Be Helpful in Early Diagnosis of Hypophosphatasia?  
*Asma Deeb, Abubaker Elfatih, (Abu Dhabi, United Arab Emirates)*
- 25** High Prenatal Exposure to Bisphenol A Reduces Anogenital Distance in Healthy Male Newborns  
*Emil Mammadov, Murat Uncu, Ceyhan Dalkan, (Nicosia, Cyprus)*
- 30** The Evaluation of Cases with Y-Chromosome Gonadal Dysgenesis: Clinical Experience over 18 Years  
*Merih Berberoğlu, Zeynep Sıklar, Ankara University Faculty of Medicine Disorders of Sexual Development Ethics Committee, (Ankara, Turkey)*
- 38** Effect of Intrahepatic Cholestasis of Pregnancy on Neonatal Birth Weight: A Meta-Analysis  
*Li Li, Yuan-Hua Chen, Yuan-Yuan Yang, Lin Cong, (Hefei, China)*
- 44** Vitamin D Deficiency in Pregnant Women and Their Infants  
*Abdurrahman Avar Özdemir, Yasemin Ercan Gündemir, Mustafa Küçük, Deniz Yıldırım Sarıcı, Yusuf Elgörmüş, Yakup Çağ, Günal Bilek, (İstanbul, Bitlis, Turkey)*
- 51** The Relationship Between Blood Pressure and Sleep Duration in Turkish Children: A Cross-Sectional Study  
*Cengiz Bal, Ahmet Öztürk, Betül Çiçek, Ahmet Özdemir, Gökmen Zararsız, Demet Ünal, Gözde Ertürk Zararsız, Selçuk Korkmaz, Dincer Göksülük, Vahap Eldem, Sevda İsmailoğulları, Emine Erdem, Mümtaz M Mazıcıoğlu, Selim Kurtoğlu, (Eskişehir, Kayseri, Edirne, Ankara, İstanbul, Turkey)*

## Clinical Review

- 59** A Meta-Analysis and an Evaluation of Trends in Obesity Prevalence among Children and Adolescents in Turkey: 1990 through 2015  
*Züleyha Alper, İlker Ercan, Yesim Uncu, (Bursa, Turkey)*

## Case Reports

- 68** A Patient with Proopiomelanocortin Deficiency: An Increasingly Important Diagnosis to Make  
*Semra Cetinkaya, Tülay Güran, Erdal Kurnaz, Melikşah Keskin, Elif Sağsak, Senay Savaş Erdeve, Jenifer P. Suntharalingham, Federica Buonocore, John C. Achermann, Zehra Aycan, (Ankara, İstanbul, Turkey, London, United Kingdom)*
- 74** 46,XY Disorder of Sex Development due to 17-Beta Hydroxysteroid Dehydrogenase Type 3 Deficiency in an Infant of Greek Origin  
*Assimina Galli-Tsinopoulou, Anastasios Serbis, Eleni P. Kotanidou, Eleni Litou, Vaia Dokousli, Konstantina Mouzaki, Pavlos Fanis, Vassos Neocleous, Nicos Skordis, (Thessaloniki, Greece, Nicosia, Cyprus)*

- 79** Transient Neonatal Diabetes due to a Mutation in *KCNJ11* in a Child with Klinefelter Syndrome  
*Amanda R. Dahl, Radhika Dhamija, Alaa Al Nofal, Siobhan T. Pittock, W. Frederick Schwenk, Seema Kumar,*  
*(Minnesota, Arizona, South Dakota, USA)*
- 83** CYP24A1 Mutation in a Girl Infant with Idiopathic Infantile Hypercalcemia  
*Jens Otto Broby Madsen, Sabrina Sauer, Bodo Beck, Jesper Johannesen, (Herlev, København Denmark, Cologne, Germany)*
- 87** Metachronous Synovial Sarcoma After Treatment of Mixed Germ Cell Tumor in a Child with Complete Gonadal Dysgenesis  
*Feryal Karahan, Elvan Çağlar Çıtak, Emel Yaman, Mehmet Alakaya, Fatih Sağçan, Eda Bengi Yılmaz, Funda Kuş,*  
*İclal Gürses, Yüksel Balcı, (Mersin, Turkey)*

## **Letter to the Editor**

- 91** Letter to the Editor Regarding "Assessment of Retinal Nerve Fiber Layer Thickness in Non-Diabetic Obese Children and Adolescents"  
*Ömer Karti, (İzmir, Turkey)*



**CONGRESS CALENDAR**

ESPE 2017 (10<sup>th</sup> International Meeting of Pediatric Endocrinology)  
14-17 September 2017, Washington, DC, USA

ISPAD 2017 (43<sup>rd</sup> Annual Conference, International Society for Pediatric and Adolescent  
Diabetes) October 18-21, 2017, Innsbruck, Austria

1,2,3...

# Ready<sup>1</sup>

## Ready To Use Growth Hormone Therapy<sup>1</sup>



  
GoQuick™


 **Novartis** Genotropin  
[Genotropin.com/US](http://Genotropin.com/US)

**GoQuick™ pen injector device is a prescription drug. It is used to deliver growth hormone therapy to children with growth hormone deficiency (GHD). GoQuick is not for use in children with Prader-Willi syndrome (PWS) or Turner syndrome (TS). See the full Prescribing Information for important information about risks and side effects. See [Genotropin.com/US](http://Genotropin.com/US) for more information.**



**Humatrope<sup>®</sup>** Cartridge  
somatropin

**Partner For Your  
Customized  
Solutions**



**Humatrope<sup>®</sup> Brief Summary of Prescribing Information**

**Humatrope<sup>®</sup> (somatropin) Cartridge**  
 Humatrope is a prescription medicine used to treat growth hormone deficiency (GHD) in children and adolescents. It is also used to treat GHD in adults. Humatrope is a synthetic form of the natural growth hormone produced by the pituitary gland. It is administered by injection into the muscle. Humatrope is available as a cartridge containing 100 units of somatropin. The cartridge is used to draw the medicine into a syringe for injection. Humatrope is a Schedule III controlled substance. It is important to use Humatrope exactly as directed by your healthcare provider. Do not share your Humatrope cartridge with anyone else. Humatrope may cause side effects, including pain at the injection site, headache, dizziness, and changes in vision. Humatrope may also cause more serious side effects, such as joint pain, muscle pain, and changes in blood sugar levels. Humatrope may interact with other medicines you are taking. Tell your healthcare provider about all the medicines you are taking. Humatrope is not recommended for use in children and adolescents with certain medical conditions, such as active malignancy, proliferative retinopathy, or proliferative vitreoretinopathy. Humatrope is not recommended for use in adults with certain medical conditions, such as active malignancy, proliferative retinopathy, or proliferative vitreoretinopathy. Humatrope is not recommended for use in pregnant women or women who are breastfeeding. Humatrope is not recommended for use in children and adolescents who are taking certain medicines, such as phenytoin, valproic acid, or carbamazepine. Humatrope is not recommended for use in adults who are taking certain medicines, such as phenytoin, valproic acid, or carbamazepine. Humatrope is not recommended for use in children and adolescents who are taking certain medicines, such as phenytoin, valproic acid, or carbamazepine. Humatrope is not recommended for use in adults who are taking certain medicines, such as phenytoin, valproic acid, or carbamazepine.

[www.Lilly.com.tr](http://www.Lilly.com.tr)

# Her Zaman Yanında



SORUMLULUK  
NordiCare®



ARAŞTIRMA  
EĞİTİM

**SİFCO'ya her zaman sorumlulukta olduğunuz için teşekkür ederiz.**  
**Her zaman yanınızda olduğumuz için teşekkür ederiz.**

SİFCO, Türkiye'de faaliyet gösteren en büyük ve en kaliteli eğitim materyalleri üreten ve pazarlayan şirkettir. SİFCO'nun tüm ürünleri, eğitim materyalleri için en uygun fiyatları sunmaktadır.

**SİFCO'ya her zaman sorumlulukta olduğunuz için teşekkür ederiz.**  
**Her zaman yanınızda olduğumuz için teşekkür ederiz.**







**They both started  
treatment recently**

**Do you know who has already  
missed two injections?**

**Missed injections** is an important  
to understand you and their doctor for  
only 24 hours after the following  
first injection and a 48-hour  
interval.

**Starting all in the first week  
to see they –and please the  
missed two injections is a  
of treatment.**

**SEIZON**



**Today your what your next in days**



**SEIZON is a registered trademark of the manufacturer. All other trademarks are the property of their respective owners.**

